290 related articles for article (PubMed ID: 32960147)
1. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
Pereda R; González D; Rivero HB; Rivero JC; Pérez A; López LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE
J Interferon Cytokine Res; 2020 Sep; 40(9):438-442. PubMed ID: 32960147
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.
Pereda R; González D; Rivero HB; Rivero JC; Pérez A; Lopez LDR; Mezquia N; Venegas R; Betancourt JR; Domínguez RE; Nodarse H
J Interferon Cytokine Res; 2020 Dec; 40(12):578-588. PubMed ID: 33337933
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
Wang N; Zhan Y; Zhu L; Hou Z; Liu F; Song P; Qiu F; Wang X; Zou X; Wan D; Qian X; Wang S; Guo Y; Yu H; Cui M; Tong G; Xu Y; Zheng Z; Lu Y; Hong P
Cell Host Microbe; 2020 Sep; 28(3):455-464.e2. PubMed ID: 32707096
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
7. [Chloroquine as a possible treatment for COVID-19].
Coumou J; de Vries PJ
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and drug therapies in patients with the common-type coronavirus disease 2019 in Hunan, China.
Huang Q; Deng X; Li Y; Sun X; Chen Q; Xie M; Liu S; Qu H; Liu S; Wang L; He G; Gong Z
Int J Clin Pharm; 2020 Jun; 42(3):837-845. PubMed ID: 32410206
[TBL] [Abstract][Full Text] [Related]
9. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
10. Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
Xu P; Huang J; Fan Z; Huang W; Qi M; Lin X; Song W; Yi L
Microbes Infect; 2020; 22(4-5):200-205. PubMed ID: 32445881
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
Dastan F; Nadji SA; Saffaei A; Marjani M; Moniri A; Jamaati H; Hashemian SM; Baghaei P; Abedini A; Varahram M; Yousefian S; Tabarsi P
Int Immunopharmacol; 2020 Aug; 85():106688. PubMed ID: 32544867
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
13. Interferon-α2b Treatment for COVID-19.
Zhou Q; Chen V; Shannon CP; Wei XS; Xiang X; Wang X; Wang ZH; Tebbutt SJ; Kollmann TR; Fish EN
Front Immunol; 2020; 11():1061. PubMed ID: 32574262
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
Fernández-Cruz A; Ruiz-Antorán B; Muñoz-Gómez A; Sancho-López A; Mills-Sánchez P; Centeno-Soto GA; Blanco-Alonso S; Javaloyes-Garachana L; Galán-Gómez A; Valencia-Alijo Á; Gómez-Irusta J; Payares-Herrera C; Morrás-Torre I; Sánchez-Chica E; Delgado-Téllez-de-Cepeda L; Callejas-Díaz A; Ramos-Martínez A; Múñez-Rubio E; Avendaño-Solá C
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32571831
[TBL] [Abstract][Full Text] [Related]
16. Treating COVID-19 with Chloroquine.
Huang M; Tang T; Pang P; Li M; Ma R; Lu J; Shu J; You Y; Chen B; Liang J; Hong Z; Chen H; Kong L; Qin D; Pei D; Xia J; Jiang S; Shan H
J Mol Cell Biol; 2020 May; 12(4):322-325. PubMed ID: 32236562
[No Abstract] [Full Text] [Related]
17. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
Hao SR; Yan R; Zhang SY; Lian JS; Cai H; Zhang XL; Zheng L; Jia HY; Hu JH; Yu GD; Gu JQ; Ye CY; Jin CL; Lu YF; Xin JJ; Sheng JF; Yang YD
J Zhejiang Univ Sci B; 2020 Aug.; 21(8):628-636. PubMed ID: 32748578
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Owa AB; Owa OT
J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
[TBL] [Abstract][Full Text] [Related]
20. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
Ding JG; Li J; Hong L; Yu XQ; Ye EL; Sun GQ; Zhang XX; Chen L; Sun QF
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5788-5796. PubMed ID: 32495917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
